The search for effective chronic pain management is often a delicate balance between relief and risk. For millions of Americans, gabapentin has emerged as a frequently prescribed option, initially touted as a safer alternative to opioid painkillers. But, a growing body of research is raising concerns about the long-term effects of this widely used medication, particularly regarding cognitive health and potential for unintended consequences. Understanding the evolving landscape of gabapentin use—from its initial promise to recent warnings—is crucial for both patients and healthcare providers.
Gabapentin, originally developed as an anticonvulsant, is FDA-approved for treating seizure disorders and postherpetic neuralgia, the nerve pain that can linger after a shingles outbreak. It works by calming overactive nerve activity, mimicking the neurotransmitter GABA, which helps regulate brain signals. But its application has expanded significantly, becoming a common off-label prescription for a variety of chronic pain conditions, including fibromyalgia, diabetic neuropathy, and chronic back pain. This rise in popularity coincided with increased awareness of the opioid epidemic and efforts to reduce reliance on these highly addictive drugs. Between 2010 and 2024, prescriptions for gabapentin more than doubled, reaching a point where it became the fifth most dispensed drug in U.S. Retail pharmacies in 2024, with approximately 15.5 million Americans taking the medication, according to a September 2025 report by CDC researchers in Annals of Internal Medicine.
Cognitive Risks and Younger Patients
Even as initially seen as a safer option, recent studies are challenging that perception. A concerning 2025 study published in Regional Anesthesia & Pain Medicine linked long-term gabapentin use for chronic low back pain with an increased risk of cognitive impairment and dementia, particularly in younger adults. Researchers tracked over 52,000 adults for a decade, finding that those with six or more gabapentin prescriptions had more than double the risk of dementia and more than triple the risk of mild cognitive impairment compared to those who didn’t take the drug. This risk was especially pronounced in individuals aged 35 to 49 and 50 to 64.
The study, based on data from the TriNetX national database of de-identified patient records, carefully excluded individuals with pre-existing conditions like dementia, epilepsy, stroke, or cancer to isolate the potential effects of gabapentin. The researchers found a clear dose-response relationship: the more prescriptions a patient received, the higher their risk of cognitive decline. Patients with 12 or more prescriptions faced an even greater incidence of both mild cognitive impairment and dementia.
Prescribing Cascades and Unintended Edema
The concerns extend beyond cognitive health. A separate analysis in JAMA Network Open highlighted the potential for “prescribing cascades,” where side effects of one medication are treated with another, creating a cycle of unintended consequences. The study focused on military veterans treated with gabapentin and found that clinicians often failed to recognize gabapentinoid-induced edema (swelling) and instead attributed it to conditions like congestive heart failure or venous stasis, leading to inappropriate treatment with diuretics. Nearly one in four patients experienced potential harm as a result of this misdiagnosis and subsequent treatment.
Global Uncertainty and Self-Harm Concerns
These findings echo concerns voiced internationally. A 2025 review of qualitative studies in the European Journal of Pain revealed a recurring theme of uncertainty among clinicians worldwide regarding the optimal way to start, monitor, and taper gabapentinoid use. This lack of clear guidance contributes to inconsistent prescribing practices and potential for adverse outcomes. A U.K. Self-controlled case series published in the BMJ in April 2025 re-examined the link between gabapentin and self-harm, finding an increased risk in the periods before, during, and after treatment, highlighting the importance of careful patient monitoring throughout the course of therapy.
The common side effects of gabapentin—drowsiness, dizziness, blurred vision, and difficulty concentrating—can also significantly impact quality of life. As someone who personally navigated chronic pain and subsequently used gabapentin for approximately two years before discontinuing it due to a lack of perceived benefit, I understand the complexities of finding effective pain management solutions. It’s essential that medical professionals carefully weigh the potential benefits against the risks, ensuring that treatment doesn’t inadvertently create modern problems.
The increasing scrutiny surrounding gabapentin underscores the require for a more nuanced approach to chronic pain management. While it may offer relief for some, the potential for cognitive impairment, prescribing cascades, and other adverse effects demands careful consideration and ongoing research. Patients should engage in open and honest conversations with their doctors about the risks and benefits of gabapentin, as well as explore alternative pain management strategies.
Looking ahead, further research is needed to fully understand the long-term effects of gabapentin and to develop more targeted and effective pain management approaches. The FDA continues to monitor reports of adverse events and will likely provide updated guidance as new evidence emerges. The next update from the FDA regarding gabapentin safety is expected in the fourth quarter of 2026.
Have you or someone you know been affected by gabapentin use? Share your experiences and thoughts in the comments below.
